HUE066587T2 - Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor - Google Patents
Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitorInfo
- Publication number
- HUE066587T2 HUE066587T2 HUE18851555A HUE18851555A HUE066587T2 HU E066587 T2 HUE066587 T2 HU E066587T2 HU E18851555 A HUE18851555 A HU E18851555A HU E18851555 A HUE18851555 A HU E18851555A HU E066587 T2 HUE066587 T2 HU E066587T2
- Authority
- HU
- Hungary
- Prior art keywords
- exon
- selective inhibitor
- mutant egfr
- egfr selective
- mutant
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017168606 | 2017-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE066587T2 true HUE066587T2 (hu) | 2024-08-28 |
Family
ID=65527547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18851555A HUE066587T2 (hu) | 2017-09-01 | 2018-08-31 | Exon-18- és/vagy exon-21-mutáns EGFR-szelektív inhibitor |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11701359B2 (hu) |
| EP (1) | EP3677266B1 (hu) |
| JP (1) | JP7065103B2 (hu) |
| KR (1) | KR102676530B1 (hu) |
| CN (2) | CN117159551A (hu) |
| AU (1) | AU2018325819B2 (hu) |
| CA (1) | CA3074418C (hu) |
| DK (1) | DK3677266T5 (hu) |
| ES (1) | ES2972895T3 (hu) |
| FI (1) | FI3677266T3 (hu) |
| HU (1) | HUE066587T2 (hu) |
| IL (1) | IL272929B2 (hu) |
| JO (1) | JOP20200044A1 (hu) |
| MX (1) | MX2020002296A (hu) |
| MY (1) | MY199676A (hu) |
| NZ (1) | NZ762195A (hu) |
| PH (1) | PH12020500419A1 (hu) |
| PL (1) | PL3677266T3 (hu) |
| PT (1) | PT3677266T (hu) |
| SG (1) | SG11202001861WA (hu) |
| TW (1) | TWI838345B (hu) |
| WO (1) | WO2019045036A1 (hu) |
| ZA (1) | ZA202001445B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190073A1 (ar) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| FI3677266T3 (fi) | 2017-09-01 | 2024-03-22 | Taiho Pharmaceutical Co Ltd | Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori |
| FI3902548T3 (fi) * | 2018-12-28 | 2025-07-17 | Taiho Pharmaceutical Co Ltd | Hoitoresistentin L718- ja/tai L792-mutaation omaavan EGFR:n inhibiittori käytettäväksi syövän hoitamisessa |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| BR112023021111A2 (pt) | 2021-04-13 | 2023-12-19 | Nuvalent Inc | Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2 |
| CN115785107B (zh) * | 2022-12-15 | 2024-11-12 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
| TW202515577A (zh) * | 2023-06-27 | 2025-04-16 | 日商大鵬藥品工業股份有限公司 | 患有具有egfr畸變的非小細胞肺癌之個體的治療方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| KR20070113295A (ko) | 2005-03-17 | 2007-11-28 | 노파르티스 아게 | 티로신/트레오닌 키나제 억제제, 특히 b-raf 키나제억제제로서의n-[3-(1-아미노-5,6,7,8-테트라히드로-2,4,4b-트리아자플루오렌-9-일)-페닐]벤즈아미드 |
| PL1800675T4 (pl) | 2005-12-23 | 2012-02-29 | Nutricia Nv | Kompozycja zawierająca wielonienasycone kwasy tłuszczowe, białka, mangan, i/lub molibden oraz nukleozydy/nukleotydy do leczenia otępienia |
| MY152972A (en) | 2009-07-10 | 2014-12-15 | Taiho Pharmaceutical Co Ltd | Azabicyclo compound and salt thereof |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| EP2662357B1 (en) | 2011-01-07 | 2016-08-03 | Taiho Pharmaceutical Co., Ltd. | Bicyclic compounds or salts thereof for use in the treatment of cancer |
| JP5878178B2 (ja) | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | 1,2,4−トリアジン−6−カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| WO2013118817A1 (ja) | 2012-02-07 | 2013-08-15 | 大鵬薬品工業株式会社 | キノリルピロロピリミジン化合物又はその塩 |
| CN104136438B (zh) | 2012-02-23 | 2016-04-06 | 大鹏药品工业株式会社 | 喹啉基吡咯并嘧啶基稠环化合物或其盐 |
| AU2014219754B2 (en) | 2013-02-22 | 2016-05-05 | Taiho Pharmaceutical Co., Ltd. | Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method |
| TWI603971B (zh) | 2013-08-22 | 2017-11-01 | Taiho Pharmaceutical Co Ltd | Novel quinoline substituted compounds |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ, インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| AP2017009690A0 (en) | 2014-06-19 | 2017-01-31 | Ariad Pharma Inc | Heteroaryl compounds for kinase inhibition |
| JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
| FI3677266T3 (fi) | 2017-09-01 | 2024-03-22 | Taiho Pharmaceutical Co Ltd | Eksoni 18- ja/tai eksoni 21 -egfr-mutantille selektiivinen inhibiittori |
-
2018
- 2018-08-31 FI FIEP18851555.5T patent/FI3677266T3/fi active
- 2018-08-31 ES ES18851555T patent/ES2972895T3/es active Active
- 2018-08-31 DK DK18851555.5T patent/DK3677266T5/da active
- 2018-08-31 TW TW107130585A patent/TWI838345B/zh active
- 2018-08-31 JP JP2019539655A patent/JP7065103B2/ja active Active
- 2018-08-31 CN CN202310869220.7A patent/CN117159551A/zh active Pending
- 2018-08-31 NZ NZ762195A patent/NZ762195A/en unknown
- 2018-08-31 WO PCT/JP2018/032314 patent/WO2019045036A1/ja not_active Ceased
- 2018-08-31 KR KR1020207008984A patent/KR102676530B1/ko active Active
- 2018-08-31 IL IL272929A patent/IL272929B2/en unknown
- 2018-08-31 US US16/642,969 patent/US11701359B2/en active Active
- 2018-08-31 EP EP18851555.5A patent/EP3677266B1/en active Active
- 2018-08-31 MY MYPI2020001066A patent/MY199676A/en unknown
- 2018-08-31 HU HUE18851555A patent/HUE066587T2/hu unknown
- 2018-08-31 JO JOP/2020/0044A patent/JOP20200044A1/ar unknown
- 2018-08-31 AU AU2018325819A patent/AU2018325819B2/en active Active
- 2018-08-31 CN CN201880064210.3A patent/CN111465397B/zh active Active
- 2018-08-31 CA CA3074418A patent/CA3074418C/en active Active
- 2018-08-31 MX MX2020002296A patent/MX2020002296A/es unknown
- 2018-08-31 PL PL18851555.5T patent/PL3677266T3/pl unknown
- 2018-08-31 SG SG11202001861WA patent/SG11202001861WA/en unknown
- 2018-08-31 PT PT188515555T patent/PT3677266T/pt unknown
-
2020
- 2020-03-02 PH PH12020500419A patent/PH12020500419A1/en unknown
- 2020-03-06 ZA ZA2020/01445A patent/ZA202001445B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3677266T3 (pl) | Selektywny inhibitor egfr z mutacją w eksonie 18 i/lub eksonie 21 | |
| IL266239A (en) | Selective inhibitor of egfr with exon 20 insertion mutation | |
| IL280134A (en) | Anti-CD112R preparations and methods | |
| ZA202002172B (en) | Pde9 inhibitor and use thereof | |
| IL288872A (en) | Imidazopyrimidines as eed inhibitors and their use | |
| HUE061331T2 (hu) | Mutáns IDH-1 gátlása | |
| GB2591554B (en) | Composiitons and methods and uses relating thereto | |
| SG11202104448WA (en) | Compositions and methods | |
| GB201817444D0 (en) | Methods and compositions | |
| IL284330A (en) | Treatment-resistant EGFR inhibitor mutant L718 and/or L792 | |
| GB201819987D0 (en) | Methods and compositions | |
| GB202102659D0 (en) | Drilling systems and methods | |
| GB201906169D0 (en) | Drilling systems and methods | |
| GB201804092D0 (en) | Methods and compositions | |
| IL276476B1 (en) | Crystalline EGFR inhibitor and its uses | |
| IL269723A (en) | Mixtures containing mutant alpha-1-antitrypsin and their use | |
| GB2579366B (en) | Drilling systems and methods | |
| GB2594831B (en) | Rheometer systems and related methods | |
| PL3720442T3 (pl) | Hamowanie mutanta idh-1 | |
| GB2587571B (en) | Drilling systems and methods | |
| GB201902266D0 (en) | New methods and uses | |
| GB202101948D0 (en) | Drilling systems and methods | |
| GB201812776D0 (en) | New methods and uses | |
| GB201817902D0 (en) | Methods and compositions | |
| GB201809880D0 (en) | Compositions and methods |